Paper Details 
Original Abstract of the Article :
AIMS: The purpose of this study was to evaluate the renal side-effects of adefovir therapy in kidney-transplant (KT) recipients with chronic hepatitis B virus (HBV) infection, who have become resistant to lamivudine therapy. PATIENTS AND METHODS: 11 kidney-transplant (KT) patients (10 men, 1 woman,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.5414/cnp71036

データ提供:米国国立医学図書館(NLM)

Managing Hepatitis B in Kidney Transplant Recipients

The world of organ transplantation is a complex and ever-evolving desert, where researchers strive to improve patient outcomes. This study examines the potential renal side effects of adefovir, an antiviral medication used to treat hepatitis B virus (HBV) infection, in kidney transplant recipients.

Researchers investigated the impact of adefovir therapy on renal function in 11 kidney transplant recipients who had developed lamivudine-resistant chronic HBV infection. This is like navigating a complex desert landscape, carefully monitoring the effects of medication on the delicate balance of organ function.

Balancing the Benefits and Risks

The study found that adefovir therapy effectively suppressed HBV replication in kidney transplant recipients, but it also caused a slight impairment of renal proximal-tubular function. This is like finding a valuable oasis but encountering a small sandstorm along the way.

Navigating the Desert of Transplantation

This study highlights the challenges of managing HBV infection in kidney transplant recipients. It underscores the need for careful monitoring of renal function and considering the potential risks and benefits of antiviral therapy.

Dr. Camel's Conclusion

This study underscores the need for careful management of HBV infection in kidney transplant recipients. It provides valuable insights into the potential renal side effects of adefovir therapy, reminding us to navigate the complex desert of transplantation with careful attention to the unique needs of each patient.

Date :
  1. Date Completed 2009-03-31
  2. Date Revised 2019-06-08
Further Info :

Pubmed ID

19203548

DOI: Digital Object Identifier

10.5414/cnp71036

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.